Rose Petroleum Plc (LON:ROSE) CEO Matthew Idiens caught up with DirectorsTalk to talk about key areas of focus now for the company, why they view “the future with optimism”, how the Cuba project is developing, other opportunities being explored and news-flow to be expected.
Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about the recent share price movement. Stephen also talks about the potential for 39 RNS’s that could be announced over the coming months as opportunities turn
OptiBiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about the listing of SkinBiotheraputics (LON:SBTX). Stephen explains the rationale behind the launch, what this could mean for OptiBiotix investors, the timing involved and how this
Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about its European manufacturing, supply and profit sharing agreement with Sacco S.r.l. Stephen explains tells us more about the agreement and its pipeline for other agreements
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced in January that it has had two abstracts accepted for presentation at ProBiota 2017 in Berlin
Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about a string of news since Christmas, Stephen gives us an overview of the company’s progress and plans for 2017. In December 2016 OptiBiotix Health plc
OptiBiotix Health plc (LON:OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announces that it has entered into a joint development agreement (the “Agreement”) with a multinational. The Agreement allows for
Optibiotix Health Plc (LON:OPTI) CEO Stephen OHara today spoke about an article published in the telegraph. The article refers to a major Lancet study which backed the safety of statins where according to a group of
OptiBiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about the recent Scientific and Commercial Update. Stephen talks us through the update providing more detail on both the scientific and commercial sides. During over 30
Rose Petroleum PLC (LON:ROSE) CEO Matt Idiens talks with DirectorsTalk about the bigger picture. Matt explains what the proceeds of the £1m raised will be used for, updates us on the assets in Mexico, longer term
Optibiotix Health’s Stephen O’Hara discusses the new appointment of Martin Hunt as Chairman at SkinBiotics, how this fits into their strategy and what it means for shareholders in this exclusive interview with DirectorsTalk
Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about the appointment of a new chairman for its SkinBiotix division. Stephen explains the reasoning behind the decision, what this means for investors, how it fits
Rose Petroleum’s Matt Idiens discusses the highlights from their interim results, the Paradox project, opportunities in Cuba and being well-positioned for the year ahead in this exclusive interview with DirectorsTalk
Rose Petroleum Plc (LON:ROSE) CEO Matt Idiens caught up with DirectorsTalk to discuss the latest interim results. Matt talks though the highlights, provides update on Paradox and mining operations, explains the opportunity in Cuba and shares
OptiBiotix Health’s Stephen O’Hara discusses the key points from their half-year report in this exclusive interview with DirectorsTalk
Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about the release of it’s 6 month interim’s. Stephen talks about the IP, scientific, and commercial aspects of the results. OptiBiotix Health Plc was formed in
Optibiotix Health Plc (LON:OPTI) is the topic of conversation with Hybridan researcher and corporate broker Nathan Derren. The company has made great progress since its IPO and Nathan explains what the main drivers will be going
OptiBiotix Health’s Stephen O’Hara discusses their new strategy and what this will mean for investors in this exclusive interview with DirectorsTalk
OptiBiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about it’s new strategy, the thinking behind this, what it means for shareholders and when we can expect to see a listing. The company develop compounds which
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.